Combined Approach to Leukemic Differentiation Using Transcription Factor PU.1-Enhancing Agents.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
16 Jun 2022
Historique:
received: 21 12 2021
revised: 13 06 2022
accepted: 14 06 2022
entrez: 24 6 2022
pubmed: 25 6 2022
medline: 28 6 2022
Statut: epublish

Résumé

The transcription factor PU.1 (Purine-rich DNA binding, SPI1) is a key regulator of hematopoiesis, whose level is influenced by transcription through its enhancers and its post-transcriptional degradation via microRNA-155 (miR-155). The degree of transcriptional regulation of the

Identifiants

pubmed: 35743167
pii: ijms23126729
doi: 10.3390/ijms23126729
pmc: PMC9224232
pii:
doi:

Substances chimiques

MIRN155 microRNA, human 0
MicroRNAs 0
Proto-Oncogene Proteins 0
Trans-Activators 0
proto-oncogene protein Spi-1 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Czech Science Foundation
ID : 19-03586S
Organisme : Ministry of Health
ID : NV19-08-00144, NU21-08-00312
Organisme : Charles University
ID : GAUK 1672119 , SVV260521 , UNCE/MED/016 , Progres Q26

Références

PLoS One. 2018 Feb 2;13(2):e0190934
pubmed: 29394256
Blood. 2009 Apr 16;113(16):3655-65
pubmed: 19221035
J Hematol Oncol. 2012 May 08;5:22
pubmed: 22569057
Blood. 2014 Oct 23;124(17):2705-12
pubmed: 25224413
Nat Genet. 2004 Jun;36(6):624-30
pubmed: 15146183
Biol Chem. 2014 Nov 1;395(11):1265-74
pubmed: 25205721
Leukemia. 2012 Apr;26(4):644-53
pubmed: 21960247
Aging (Albany NY). 2020 Nov 5;13(1):241-261
pubmed: 33173017
Leukemia. 2007 May;21(5):1050-9
pubmed: 17361223
Blood. 2011 Mar 10;117(10):2827-38
pubmed: 21239694
Molecules. 2016 Apr 30;21(5):
pubmed: 27144550
J Nanobiotechnology. 2019 Apr 22;17(1):57
pubmed: 31010426
Blood. 2016 Mar 3;127(9):1173-82
pubmed: 26631113
Oncogene. 2014 Sep 25;33(39):4735-45
pubmed: 24121269
Cell Stem Cell. 2014 Jun 5;14(6):824-37
pubmed: 24704494
Nat Commun. 2018 Jan 9;9(1):110
pubmed: 29317678
Cancer Lett. 2020 Jun 1;479:61-70
pubmed: 32014461
Sci Rep. 2018 Sep 3;8(1):13159
pubmed: 30177851
Blood. 2017 Jun 8;129(23):3074-3086
pubmed: 28432220
Oncogene. 1997 Jan 9;14(1):123-31
pubmed: 9010239
Oncogene. 2017 Nov 23;36(47):6617-6626
pubmed: 28783166
Nat Med. 2015 Oct;21(10):1172-81
pubmed: 26343801
Int J Biochem Cell Biol. 2008;40(1):22-7
pubmed: 17374502
Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1486-91
pubmed: 16432184
Cancer Cell. 2016 Dec 12;30(6):849-862
pubmed: 27916615
Leukemia. 2012 Aug;26(8):1804-11
pubmed: 22343522
Genes Dev. 2008 Aug 1;22(15):2085-92
pubmed: 18676813
Blood. 2011 Aug 25;118(8):2275-84
pubmed: 21730352
Blood. 2011 Apr 7;117(14):3816-25
pubmed: 21296997
Nat Immunol. 2003 Oct;4(10):1029-36
pubmed: 12958595
J Exp Med. 2008 Mar 17;205(3):585-94
pubmed: 18299402

Auteurs

Petra Bašová (P)

BIOCEV, 1st Medical Faculty, Charles University, 25250 Vestec, Czech Republic.

Helena Paszeková (H)

BIOCEV, 1st Medical Faculty, Charles University, 25250 Vestec, Czech Republic.

Lubomír Minařík (L)

BIOCEV, 1st Medical Faculty, Charles University, 25250 Vestec, Czech Republic.

Martina Dluhošová (M)

BIOCEV, 1st Medical Faculty, Charles University, 25250 Vestec, Czech Republic.

Pavel Burda (P)

BIOCEV, 1st Medical Faculty, Charles University, 25250 Vestec, Czech Republic.

Tomáš Stopka (T)

BIOCEV, 1st Medical Faculty, Charles University, 25250 Vestec, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH